Skip to content
Screener

Ardelyx ARDX Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$1.2B-4.0%
Enterprise value$1.36B-0.6%
P/S2.7×-0.6×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:ResearchAndDevelopmentExpenseAdjusted.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less
Cost of product sales(2)3,6893,2456,5645,585
Other cost of revenue(3)2,0709,1584,00619,121
Research and development(4)23,19513,25140,78124,586
Selling(4)66,94957,952134,344114,752
General and administrative(4)22,08316,76445,39934,701
Stock-based compensation15,31611,68729,47423,775
Loss from operations(12,425)(14,395)(45,218)(50,744)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's business segments — R&D?
Ardelyx (ARDX) reported business segments — R&D of $23.2M in Q2 2026.
How has Ardelyx's business segments — R&D changed year-over-year?
Ardelyx's business segments — R&D increased by 75.0% year-over-year, from $13.25M to $23.2M.
What is the long-term trend for Ardelyx's business segments — R&D?
Over 3 years (2022 to 2025), Ardelyx's business segments — R&D has grown at a 27.6% compound annual growth rate (CAGR), from $28.78M to $59.81M.
What does business segments — R&D mean?
Includes all costs associated with the discovery, clinical development, and regulatory approval processes for new drug candidates. This investment is critical for maintaining a pipeline of innovative therapies and long-term competitive advantage. Higher spending generally indicates an active commitment to expanding the therapeutic portfolio.

Ask your AI about Ardelyx's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude